The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery by Eckenfelder, Agathe et al.
Citation: Molecular Therapy–Nucleic Acids (2012) 1, e31;  doi:10.1038/mtna.2012.24
© 2012 American Society of Gene & Cell Therapy  All rights reserved 2158-3188/11
www.nature.com/mtna
INTRODUCTION
A variety of mRNAs with different exon composition, stability 
or subcellular localization, as well as small RNAs with regu-
latory roles can be produced from a single transcription unit, 
thus increasing the complexity of genome information.1 A 
large proportion of disease-associated mutations in humans 
affect the processing of pre-mRNAs2 often by disturbing the 
delicate balance of alternative splicing, which is observed in 
over 90% of transcription units.3 The modulation of pre-mRNA 
splicing has been proposed as an approach to compensate 
the deleterious effect of mutations.4 It can be achieved with a 
high-specificity, using antisense oligoribonucleotides (AON) 
that mask key splicing signals through Watson-Crick pairing 
with the pre-mRNA. The successful AON-mediated restora-
tion of correct splicing has been reported in a number of cel-
lular and animal models of genetic diseases.5 In particular 
cases, AONs can be exploited to induce exon skipping in such 
a way that it removes deleterious mutations or re-establish 
a reading frame disrupted by a deletion. This approach is 
actively pursued in clinical trials involving patients with Duch-
enne muscular dystrophy (DMD).6–9
A limitation of AON-based therapies for treating chronic 
genetic  diseases  such  as  DMD  is  the  need  for  repeated 
administration of high doses of oligonucleotides (up to sev-
eral mg/kg). A sustained intracellular production of antisense 
sequences can be obtained using modified small nuclear (sn) 
RNAs such as U1, U2, or U7 delivered by viral vectors.10–12 
We and others have demonstrated the efficacy of chimeric 
snRNAs for sustained therapeutic exon skipping in animal 
models of DMD, following local or systemic gene delivery with 
AAV vectors targeting skeletal muscles, heart, and brain.13–16 
Yet, clinical applications to DMD patients by systemic adminis-
tration of AAV vectors carrying a modified snRNA will require 
very high doses that are potentially toxic and represent a 
challenge for the current capacity of vector manufacturing. 
Reducing the injected dose is paramount to the success of 
current translational studies that aim at implementing vector 
mediated exon skipping into the clinic. It may be achieved in 
part by using the appropriate AAV serotype for muscle and 
heart delivery,14 but also by optimizing the amount of chimeric 
snRNAs transcribed and assembled into active snRNPs.
The Sm-class snRNA genes are transcribed by RNA poly-
merase II in association with a specialized complex called Inte-
grator. The polymerase initiate transcription on short bipartite 
promoters composed of proximal and distal sequence ele-
ments (PSE and DSE, respectively), while the Integrator com-
plex recognizes signals in the internal stem-loop structures of 
the coding sequence, as well as in a conserved 3′ box and 
mediates co-transcriptional 3′ processing.17 The snRNAs are 
then exported to the cytoplasm where they undergo further 
modifications and assemble with Sm proteins before re-entry 
into the nucleus. Proper assembly requires a consensus Sm 
binding site.18 U7 is a non-spliceosomal snRNA that functions 
as a processing factor of the non-polyadenylated replication 
dependent histone mRNA. It is the shortest and simplest of 
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snRNAs and it includes a 5′ antisense sequence recogniz-
ing the histone pre-mRNA, a non-consensus Sm-binding site 
and a stem-loop structure containing determinants for the 
co-transcriptional 3′ endonucleolytic cleavage. The low abun-
dance of the U7 small nuclear ribonucleoproteins (snRNP) 
is reversed when a consensus spliceosomal Sm sequence 
is introduced (SmOPT) and substitutions of the original 5′ 
sequences result in abundant and stable shuttles for ectopic 
antisense delivery.10,19
Here, we have added a strong muscle- and heart-specific 
transcriptional  enhancer  upstream  of  the  DSE  in  chime-
ric U7 genes carrying antisense sequences for exon skip-
ping on the human or murine DMD pre-mRNAs. We have 
observed that although the amount of transcripts produced 
by the U7 promoter is readily enhanced, many of them are 
not processed and may not be assembled in snRNPs with 
exon-skipping activity on the DMD gene pre-mRNA. In addi-
tion, the SmOPT sequence required for stabilizing the U7 
transcript  induces  the  generation  of  3′-processed  species 
missing 20 nucleotides (nt), whose stability or activity may 
be affected. We conclude that the potential for enhancing 
exon-skipping activity of chimeric U7 cassettes is limited by 
the snRNA processing capacity of the host cell.
RESULTS
Design and validation of an enhanced U7 cassette
Brun et al. have shown that transcription from the U7 pro-
moter can be increased by placing an enhancer upstream of 
the Distal Sequence Element.20 Based on this observation, 
we have constructed a U7 cassette in which a strong mus-
cle-specific  transcriptional  enhancer  was  inserted  (Figure 
1a). Salva et al. have designed such an enhancer by fusing 
elements from the α-myosin heavy chain (α-MHC) and the 
muscle creatin kinase (MCK) enhancers, and shown that, in 
combination with the CK promoter it results in a very strong 
and mostly tissue-specific enhancement of gene expression 
when used in AAV vectors.21 We have assembled a similar 
enhancer [muscle- and heart-specific enhancer (MHCK), see 
Materials and Methods] and its activity was first validated in 
murine C2C12 myoblasts using an AAV vector carrying green 
fluorescent protein (GFP) under the control of the human 
PGK  promoter  (Supplementary  Figure  S1).  The  MHCK 
enhancer was then introduced upstream of a U7snRNA cas-
sette containing an antisense sequence able to induce skip-
ping of exon 51 on the human DMD pre-mRNA by masking 
an exonic splicing enhancer (U7ex51)22 (Figure 1a). Lenti-
viral vectors carrying U7ex51 with or without the enhancer 
were constructed and human CHQ myoblasts were trans-
duced  with  increasing  multiplicities  of  infection  (MOI,  see 
Materials and Methods). Three days post-transduction, cells 
were differentiated into myotubes for 3 days and exon-skip-
ping efficiency was analyzed by reverse transcription (RT)-
PCR. The efficiency of skipping was evaluated by estimating 
the  relative  intensities  of  the  skipped  versus  nonskipped 
diagnostic bands appearing after electrophoresis of RT-PCR 
products on agarose gels (Figure 1b). The results indicate a 
dose-dependent exon skipping for both vectors, with a higher 
activity for the one containing the MHCK enhancer, detect-
able at lower doses.
In order to test the efficiency of the MHCK enhancer in 
the skeletal muscle of mdx mice, we introduced it into an 
AAV vector containing the U7DTex23 cassette that carries 
antisense sequences able to induce skipping of exon 23 in 
the murine Dmd pre-mRNA13 (Figure 2a). AAV 2/5 vectors 
were produced with or without enhancer and used to trans-
duce murine C2C12 myoblasts (see Materials and Methods). 
The U7DTex23 transcripts were analyzed by northern blot 
on total RNA isolated from transduced cells and normalized 
to the quantity of U2 snRNA (Figure 2b). Unexpectedly, two 
small RNA species reacted with a probe in the Dmd anti-
sense region (Figure 2a and Materials and Methods). The 
predicted 86 nt U7DTex23 transcript was present along with 
equivalent quantities of a shorter species of ~66 nt. Alto-
gether, the amounts of chimeric U7 RNA were enhanced in 
the presence of the MHCK sequences. This effect was clearly 
visible at the lower vector dose, presumably because non-
saturating levels of transcripts are made under these con-
ditions. Of note, high-molecular weight RNA recognized by 
Figure  1  Muscle-  and  heart-specific  enhancer  (MHCK)  en-
hances  U7ex51-mediated  exon  skipping  on  the  Duchenne 
muscular  dystrophy  (DMD)  pre-mRNA  in  cultured  human 
myotubes.  (a)  U7ex51  expression  is  driven  by  the  U7  pro-
moter containing distal and proximal sequence elements (DSE 
and  PSE,  respectively,  shaded  boxes). The  MHCK  enhancer21 
has been placed upstream. The rightward arrowhead indicates 
the site of transcription initiation and the downward arrowhead 
is the site of 3′ processing, activated by recognition of the 3′box 
(shaded). The sequence of the U7ex51 transcript is shown, in-
cluding an antisense sequence (underlined) that corresponds to 
an exonic splicing enhancer (ESE) in exon 51 of the human DMD 
pre-mRNA  (h51AON1:  5′-UCAAGGAAGAUGGCAUUUCU-3′).22 
The optimized Sm binding sequence (SmOPT) is shown in bold.   
(b) Reverse transcription and nested PCR detection of DMD exon 
51 skipping after transduction of human CHQ cells with lentivi-
ral vectors containing the U7ex51 (upper panel) or the MHCK-
U7ex51  (lower  panel)  cassettes,  at  increasing  multiplicities  of 
infection (MOI) Controls include nontransduced cells (0) and no 
reverse transcriptase (RT–). The native human DMD mRNA con-
taining exon 51 is detected as a 886-bp fragment and the skipped 
mRNA yields a 653-bp product.
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the probe accumulated at the high dose and in the presence 
of the enhancer. Further analysis indicated that it contained 
sequences 3′ of the U7-coding sequence and therefore rep-
resented unprocessed primary U7 RNA, possibly transcribed 
from tandem or circle copies of the AAV vector genome23 
(Supplementary Figure S2). It suggests that the integrator-
mediated formation of the U7 snRNA 3′end may be limiting 
when the transcript is too abundant.
RNAs from transduced myoblasts were also analyzed by 
RT-PCR and quantitative RT-PCR (Figure 3). Consistently, 
the results indicate that the MHCK sequences increase exon 
23 skipping, particularly at the lower dose of AAV.
The SmOPT sequences induce an additional processing 
of the U7snRNA cassette
To investigate the origin of the short RNA species detected 
with the antisense probe, variants of the U7snRNA cassette 
were  analyzed.  Human  293T  cells  were  transfected  with 
plasmids expressing an unmodified U7 which retains its nat-
ural 5′ sequences targeting Histone H1 mRNA or U7SmOPT, 
the parent construct for all U7 antisense shuttles.19 An addi-
tional shorten transcript was generated only in the presence 
of the SmOPT mutations, suggesting that they were respon-
sible for the extra processing (Supplementary Figure S3). 
Since probes at the 5′ extremity of the U7snRNA were used, 
the experiment also indicated that the processing removes   
the  3′  extremity.  U7DTex23  cassettes  with  or  without  the 
SmOPT mutations were compared in AAV2/5 transductions 
of C2C12 myoblasts (Figure 4). The inclusion of the SmOPT 
mutations resulted in higher levels of chimeric U719 and the 3′ 
deleted U7 transcripts were enhanced accordingly. The higher 
molecular weight species were also proportionally increased 
in the presence of the SmOPT mutations. The cassette con-
taining  the  original  Sm  sequences  yielded  lower  levels  of 
transcripts, which were not further processed in 3′, confirm-
ing that the SmOPT mutations determine this modification.
The amounts of the different U7-derived species (86 nt, 
66 nt, and over 200 nt) were evaluated by densitometry of 
the northern blot showed in Figure 4. The 86 nt species rep-
resented 30% and 40% of all transcripts in lanes 1 and 2, 
respectively. The difference was due to the lower amounts 
of high-molecular weight unprocessed species at the lower 
MOI. In contrast, when the original Sm sequence was pres-
ent, the 86-nt band accounted for >85% of total signal.
RT-PCR analysis of the Dmd pre-mRNA skipping was con-
sistent with the U7snRNA expression analysis. The SmOPT 
construct induced a strong exon 23 skipping whereas the 
Sm construct was almost inactive (Figure 4, lower panel).
Figure  2  Enhancement  of  U7DTex23  small  nuclear  RNAs 
(snRNAs) expression in murine C2C12 cells. (a) The sequence 
of the U7DTex23 transcript is shown, including two antisense se-
quences (underlined) that encompass the donor splice site of exon 
23 (SD23, shown in italics) and the branch point region of intron 
22 (BP22) on the murine Duchenne muscular dystrophy (Dmd) 
pre-mRNA.13 The  optimized  Sm-binding  sequence  (SmOPT)  is 
shown in bold. The probe used for the northern blot analysis in 
(b) is underlined in bold. (b) Northern blot analysis of U7DTex23 
transcripts  expressed  in  C2C12  cells  transduced  with  AAV2/5-
U7DTex23  (–MHCK)  or  AAV2/5-MHCK-U7DTex23  (+MHCK)  at 
different multiplicities of infection (MOI) (105 or 106 viral genome 
per cell). NT, nontransduced cells. The blot was hybridized with 
two 32P end-labeled probes recognizing the U2 snRNA and the 
U7DTex23 chimera (underlined in bold in (a)), respectively. U2 
snRNA shows up as a 187-nt band. Two bands of 86 nt and ~66-nt 
react with the U7DTex23 probe.
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Figure  3  U7-mediated  exon  23  skipping  on  the  Duchenne 
muscular dystrophy (Dmd) pre-mRNA. (a) Reverse transcrip-
tion and nested PCR detection of Dmd exon 23 skipping after 
transduction of C2C12 cells with AAV2/5-U7DTex23 (–MHCK) or 
AAV2/5-MHCK-U7DTex23 (+MHCK) with different multiplicities of 
infection (MOI) (105 or 106 viral genome per cell). Controls include 
nontransduced cells (NT) and no reverse transcriptase (RT–). The 
native Dmd mRNA containing exon 23 is detected as a 901-bp 
fragment and the skipped mRNA yields a 688-bp product. Re-
sults are representative of at least three independent transduc-
tions. (b) Analysis of mouse exon 23 skipping by quantitative PCR. 
The graph represents the ratio between the exon 22–24 junction 
(skipped mRNA species) and the exon 22–23 junction (full-length 
mRNA species). Quantification was performed on mRNA extract 
from C2C12 cells transduced with AAV2/5-U7DTex23 or AAV2/5-
MHCK-U7DTex23 at the indicated MOI. A significant difference is 
observed at MOI 105 as shown by the P value (P = 0.023), accord-
ing to Student’s t-test. Error bars are shown as mean ± SEM (n = 
6). MHCK, muscle- and heart-specific enhancer.
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MHCK  enhances  dystrophin  rescue  in  the  skeletal   
muscle of mdx mice
In order to determine the efficiency of the MHCK containing 
construct in vivo, AAV2/8 vectors with or without the MHCK 
enhancer were produced. Mdx mice received doses of 1011, 
2 × 1010, or 5 × 109 viral genomes into the tibialis anterior. 
One month after injection, mice were sacrificed and protein 
and RNA were isolated from the injected muscles. U7DTex23 
and U2snRNA were analyzed by northern blot, and exon 23 
skipping efficiency was evaluated by RT-PCR and quantita-
tive RT-PCR (Figure 5a,b). The northern blot analysis indi-
cated that the processed U7 species was present and that 
the MHCK resulted in a modest increase of U7 levels in the 
muscle. This increase resulted in slightly higher efficiencies 
of skipping, although the differences analyzed by quantita-
tive PCR were not significant. A stronger evidence of the 
MHCK enhancement was obtained by analyzing Dystrophin 
rescue in the injected tissues by western blot. At each dose 
analyzed, animals receiving the MHCK vector had three- to 
fivefold increased levels of rescued Dystrophin (Figure 6).
DISCUSSION
The successful clinical translation of AAV-based approaches 
for exon skipping in diseases such as DMD will depend on 
our ability to improve the therapeutic index of the vectors. The 
effective dose should be sufficient to reach extended skeletal 
muscle territories and to introduce enough transcriptionally 
active copies of the vector genome in each cell nucleus, with-
out compromising safety. Minimizing the dose will therefore 
be a combination of using an AAV vector with the appropriate 
tropism14 and optimizing the snRNA transcription unit.
The promoters of snRNA genes are compact—around 250 
base pairs (bp) in length—and very active. For example, the 
U1 promoter was shown to be equivalent to the immediate 
Figure 4 The SmOPT sequence induces an additional 3′ pro-
cessing of the U7 small nuclear RNA (snRNA). Northern blot 
analysis of U7DTex23 transcripts expressed in C2C12 cells trans-
duced with AAV2/5-U7DTex23 containing the SmOPT sequence 
(AAUUUUUGGAG, Figure 1a), or the native U7 Sm sequence 
(AAUUUGUCUAG). NT, nontransduced cells. The blot was hybrid-
ized with two 32P end-labeled probes recognizing the U2 snRNA 
and the U7DTex23 chimera, respectively. U2 snRNA shows up as 
a 187-nt band. Two bands of 86 nt and ~66-nt react with the U7D-
Tex23 probe. The lower panel presents the analysis of exon 23 
skipping performed in the same RNA samples. The native Dmd 
mRNA containing exon 23 is detected as a 901-bp fragment and 
the skipped mRNA yields a 688-bp product.
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Figure  5  Muscle-  and  heart-specific  enhancer  (MHCK)  en-
hances U7DTex23-mediated exon skipping on the Duchenne 
muscular dystrophy (Dmd) pre-mRNA in the muscle of mdx 
mice. ( a)  Northern  blot  analysis  of  U7DTex23  transcripts  ex-
pressed  in  mdx  mice  muscles  treated  with  AAV2/8-U7DTex23 
(–MHCK)  or  AAV2/8-MHCK-U7DTex23  (+MHCK).  Total  injected 
vector doses in vector genomes are indicated on top. The blot 
was  hybridized  with  two  32P  end-labeled  probes  recognizing 
the U2 small nuclear RNA (snRNA) and the U7DTex23 chimera, 
respectively. U2 snRNA shows up as a 187-nt band. Two bands 
of 86 nt and ~66-nt react with the U7DTex23 probe. The lower 
panel presents the analysis of exon 23 skipping performed in the 
same RNA samples. The native Dmd mRNA containing exon 23 
is detected as a 901-bp fragment and the skipped mRNA yields a 
688-bp product. NT, nontransduced muscle; RT–, no reverse tran-
scriptase. Results are representative of at least three independent 
transductions. (b) Quantitative PCR analysis of exon 23 skipping 
in RNA samples prepared from injected muscles. The graph rep-
resents the ratio between the exon 22–24 junction (skipped mRNA 
species) and the exon 22–23 junction (full-length mRNA species). 
No statistically significant difference could be observed between 
the groups (Student’s t-test, P > 0.05). Error bars are shown as 
mean ± SEM (n = 3 per cohort).
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early CMV enhancer/promoter for expressing a lacZ reporter 
gene.24 Although the related U7 promoter is of comparable 
strength,12,19,25 Brun et al. have shown that it can be boosted 
by  a  muscle-specific  MCK  enhancer.20  Here,  we  have 
introduced  a  strong  dual  muscle-  and  heart-specific  tran-
scriptional enhancer (MHCK) upstream of a U7 shuttle for 
antisense sequences in order to evaluate the improvement 
of exon-skipping efficiency associated with a higher number 
of chimeric snRNA molecules in cultured myogenic cells and 
in the mouse skeletal muscle.
The effect of the enhancer on the amounts of snRNA pro-
duced in cultured cells or in vivo is modest relative to the one 
reported in association with the CK promoter and 5′ untrans-
lated region.21 This is likely due to the high constitutive activ-
ity of the U7 promoter. We have observed that transcription 
enhancement by the MHCK sequences also occurs in 293 
cells, indicating that the ubiquitous nature of the U7 promoter 
overrides the tissue specificity of the enhancer (Supplemen-
tary Figure S4). This is consistent with reports showing that 
both MCK and MHC enhancers lose their tissue specificity 
when combined with constitutive promoters.26
Recombinant AAV genomes are found as either linear or 
circular  monomers  and  concatemers.  High  doses  of  AAV 
vectors result in the formation of concatemers of the vec-
tor genome.23,27 With increasing doses of vector applied to 
myogenic cells we observe the formation of high-molecular 
weight RNA species containing internal U7 sequences as 
well as sequences in the 3′ box. These are consistent with 
unprocessed read through transcripts generated from AAV 
concatemers.  A  similar  dose-dependent  accumulation  of 
unprocessed  U7  transcripts  has  been  reported  following 
injection of U7-based constructs in Xenopus oocytes and it 
was attributed to a saturation of the U7 3′ end processing 
machinery.19,25 The fact that high-molecular weight U7 tran-
scripts were not observed in the injected muscle is probably 
due to the lower MOI reached in vivo, but could also reflect a 
higher U7 processing capacity in muscle fibers compared to 
cultured myotubes.
Our data also indicate the presence in transfected or AAV 
transduced cells of a U7 species lacking 20 nt at the 3′ end. 
Such 3′-deleted forms of U7 chimeras have been observed 
previously12 and we show here that they are a consequence 
of the SmOPT mutations. U7 is normally assembled into non-
spliceosomal snRNP where a specific core of Sm proteins 
interacts with the Sm sequence.28 Changing this sequence to 
SmOPT redirects U7 transcripts into snRNPs containing the 
canonical Sm proteins, which accumulate to a much higher 
levels than unmodified U7 transcripts.19 As shown in Figure 
4, the efficiency of U7 shuttles for antisense delivery critically 
depends on the presence of an SmOPT sequence.10,29 The 
shortened U7 transcripts could be generated by a mispro-
cessing of the 3′ end associated with mutations in the Sm 
sequences, as observed for U1.30 So far however, only muta-
tions in the 3′ box or in the U7 stem loop are known to affect 
processing.31 More likely, the packaging of U7SmOPT into a 
spliceosomal snRNP may expose a cryptic nucleolytic site 
in the stem loop and trigger a partial cleavage or degrada-
tion during particle maturation.18 It is unlikely that the mis-
processed U7SmOPT species remain properly assembled 
into functional snRNPs and therefore functional for antisense 
delivery.  Moreover,  the  shortened  U7  RNAs  are  probably 
destabilized since the 3′ stem loop of snRNAs acts as a pro-
tection  against  exonucleases.  Therefore,  the  steady-state 
ratio of full-length versus misprocessed U7 RNA observed 
by northern blot may in fact underestimate the proportion of 
transcripts that undergo removal of the terminal 20 nt.
Our study indicates that potentially inactive by-products of 
U7SmOPT shuttles may be produced following gene transfer. 
Further understanding of the formation of these molecules 
may allow improving the potency of U7-based chimera for 
antisense delivery.
MATERIALS AND METHODS
Primer oligonucleotides
F1 5′-TTTACTAGTCCCTTCAGATTAAAAATAACTGA-3′
R1 5′-CCCGTAGTGGGACAGCAGGGCCCCAAGGTT-3′
F2 5′-CCCTGCTGTCCCACTACGGGTCTAGGCTGC-3′
R2 5′-CCCTCTAGAGATCCACCAGGGACAGGGTTAT-3′
FMCKdel63 5′-CCCCAACACCTGCTGCCTGCTAAAAATAACCCTG
TCCCTGGTGG-3′
RMCKdel63 5′-CCACCAGGGACAGGGTTATTTTTAGCAGGCAGCA
GGTGTTGGGG-3′
FDTex23Sm 5′gcttacctaaatagaagttcatttacactaacaatttgtctagcaggttttc
tgacttcg-3′
RDTex23Sm 5′cgaagtcagaaaacctgctagacaaattgttagtgtaaatgaacttctat
ttaggtaagc-3′
HIV_LTR_F 5′-AGCTTGCCTTGAGTGCTTCAA-3′
HIV_LTR_R 5′-AGGGTCTGAGGGATCTCTAGTTACC-3′
DTex23F 5′-GGCCAAACCTCGGCTTA-3′
DTex23R 5′-GTTAGTGTAAATGAACTTC-3′
PolyA-F 5′-ATTTTATGTTTCAGGTTCAGGGGGAGGTG-3′
PolyA-R 5′-GCGCAGAGAGGGAGTGGACTAGT-3′
Ex46Fo 5′-AGGAAGCAGATAACATTGCT-3′
Ex53Ro 5′-TTTCATTCAACTGTTGCCTC-3′
Ex47Fi 5′-TTACTGGTGGAAGAGTTGCC-3′
Ex52Ri 5′-TGATTGTTCTAGCCTCTTGA-3′
Ex20Fo 5′-CAGAATTCTGCCAATTGCTGAG-3′
Ex26Ro 5′-TTCTTCAGCTTGTGTCATCC-3′
Ex20Fi 5′-CCCAGTCTACCACCCTATCAGAGC-3′
Ex26Ri 5′-CCTGCCTTTAAGGCTTCCTT-3′
Figure 6   Muscle- and heart-specific enhancer (MHCK)-medi-
ated enhancement of Duchenne muscular dystrophy (Dmd) 
exon skipping in mdx mice leads to an increased rescue of 
Dystrophin protein in treated muscles. Western blot analysis 
of dystrophin levels in muscles of mdx mice treated with AAV2/8-
U7DTex23  (–MHCK)  or  AAV2/8-MHCK-U7DTex23  (+MHCK),  at 
doses of 2 × 1010 or 1 × 1011 vg/muscle. Samples from two different 
animals are analyzed for each condition. The wild type C57 mouse 
Dystrophin is shown as a positive control and the endogenous 
α-actinin is detected for normalization.
1011 2.1010
++ − − ++ − −
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MHCK
Dystrophin
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Vector constructions. The MHCK enhancer was obtained by 
fusing the 188 bp long-murine α-MHC enhancer, and the 207 
bp murine MCK enhancer, as described by Salva et al.21 The 
sequences were amplified from C2C12 genomic DNA using 
the PCR Master Mix (Promega, Madison, WI) following the 
manufacturer’s instructions, and primers F1 and R1 (α-MHC 
enhancer) or F2 and R2 (MCK enhancer). The two amplicons 
were fused by PCR using primers F1 and R2 and introduced 
upstream of the U7snRNA cassette in the AAV-U7DTex23 
vector, previously described as AAV-U7-SD23/BP22.13 The 
α-MHC-MCK fusion was further modified by deleting a 63 bp 
region as described,21 using the QuikChange II Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) and the primers 
FMCKdel63 and RMCKdel63.
A deletion of three cytosines between the left and right 
E-boxes  of  the  MCK  enhancer  was  observed  in  the  final 
AAV-MHCK-U7DTex23 construct, compared to the published 
NCBI sequence (GenBank: AF188002.1). This deletion was 
also observed in C2C12 genomic DNA and was considered 
a polymorphism.
U7ex51 was derived from U7DTex23 with the mouse dys-
trophin antisense sequences replaced by a sequence tar-
geting a splicing enhancer (underlined) in human dystrophin 
exon  51  (5′-GCAGGTACCTCCAACATCAAGGAAGATGGC
ATTTCTAGTTTGGAG-3′).22 U7ex51 was introduced in the 
pRRLSIN-cPPT-PGK-GFP-WPRE  lentiviral  vector32  to  cre-
ate pRRLSIN-U7ex51. The MHCK enhancer was introduced 
upstream of the U7snRNA cassette to generate pRRLSIN-
MHCK-U7ex51.
The SmOPT site of the U7DTex23 sequence was changed 
into the canonical Sm sequence in the AAV-U7DTex23 vector 
by site-specific mutagenesis using the primers FDTex23Sm 
and RDTex23Sm.
The  scAAV-PGK-GFP  plasmid  was  constructed  by 
introducing  the  PGK-GFP  fragment  from  pRRLSIN-cPPT-
PGK-GFP-WPRE  into  the  self-complementary  vector 
scAAV-LP1-hFIX,33 from which the LP1-hFIX sequence was 
removed. The MHCK enhancer was inserted upstream of the 
PGK promoter to obtain scAAV-MHCK-PGK-GFP.
Lentiviral vectors preparation. Lentiviral virions were pro-
duced by calcium phosphate transfection of HEK293T cells 
with the envelope plasmid pMD.G (VSV-G34), the packaging 
plasmids pHDM-gpm2 (codon-optimized HIV-1 Gag-Pol) and 
pRC/CMV-REV1B (REV) (both gifts from Dr Jeng-Shin Lee, 
Harvard Medical School), and the vector plasmid pRRLSIN-
U7ex51. Viral supernatants were harvested 20, 28, and 36 
hours post-transfection, centrifuged 5 minutes at 1,500 rpm, 
filtered through a 0.45-μm filter, and ultracentrifuged 2 hours 
at 19,500 rpm at 12 °C. Pellets were resuspended in phos-
phate-buffered saline (PBS) 1% bovine serum albumin and 
stored at −80 °C. The infectious titers were determined by 
quantitative PCR using the SYBR Green PCR Master Mix 
(Applied Biosystems, Life Technologies, Carlsbad, CA) and 
primers specific for the lentiviral genome HIV_LTR_F and 
HIV_LTR_R. The albumin endogenous gene was used for 
normalization.
AAV vectors preparations. AAV vectors were produced by 
calcium phosphate transfection of HEK293T cells with the 
transgene plasmid, the capsid plasmid AAV2/8 (LTAAVhelp2-
835) or AAV2/5 (Napoli 2/536), and the plasmid for adenovirus 
helper function (pHGTI-Adeno137). After 72 hours cells and 
media were harvested and centrifuged at 1,800 rpm for 10 
minutes at 4 °C and the pellets resuspended in 40 ml of 
TD buffer (140.4 mmol/l NaCl, 4.9 mmol/l KCl, 0.7 mmol/l 
K2HPO4, 3.4 mmol/l MgCl2, 24.7 mmol/l Tris—pH 7.5). After 
five freeze/thaw cycles of the suspension (30 minutes at –80 
°C followed by 30 minutes at 37 °C) 2,000 U of benzonase 
were added, the suspension was incubated for 30 minutes at 
37 °C and centrifuged for 20 minutes at 3,000g. The super-
natant  was  filtered  through  a  0.45-μm  filter  and  the  AAV 
preparations were purified by affinity chromatography using 
the AKTA explorer chromatography system (GE Healthcare, 
Waukesha, WI) and a prepacked AVB sepharose affinity col-
umn (HiTrap; GE Healthcare). The collected fractions of AAV 
vectors sample were pooled and dialysed in PBS at 4 °C 
for 16 hours. The viral genome titers were assessed by real-
time PCR using the SYBR Green PCR Master Mix (Applied 
Biosystems). For titration of the AAV-U7DTex23 and AAV-
MHCK-U7DTex23  vectors,  primers  specific  of  the  DTex23 
antisense  sequence  were  used:  DTex23F  and  DTex23R. 
For the scAAV-PGK-GFP and scAAV-MHCK-PGK-GFP vec-
tors, primers in the polyA sequence were used: PolyA-F and 
PolyA-R.
Cell culture and transduction. All the cells were cultivated 
at 37 °C and 5% CO2. 293T cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal calf serum (Invitrogen). CHQ 
cells were grown in F-10 medium (Invitrogen) supplemented 
with 20% fetal calf serum (Invitrogen). Differentiation of CHQ 
cells  was  induced  in  DMEM  without  pyruvate  (Invitrogen) 
supplemented with 100 μg/ml of human apolipotransferrin 
(Sigma, St Louis, MI) and 10 μg/ml of bovin insulin (Sigma). 
C2C12 cells were grown in DMEM supplemented with 20% 
fetal calf serum (Invitrogen). Differentiation of C2C12 was 
induced  in  DMEM  supplemented  with  2%  horse  serum 
(Sigma).
For lentiviral vector transduction, 30,000 CHQ cells were 
seeded in each well of a 12-wells plate. After 24 hours, the 
lentiviral vector preparation was administered in a total vol-
ume of 250 μl of proliferation medium at the chosen MOI. After 
6-hour incubation 1 ml of proliferation medium was added 
per well. Seventy two hours post-transduction the medium 
was replaced with differentiation medium for 72 additional 
hours. Cells were then harvested for analysis.
For AAV vector transduction, 100,000 C2C12 cells were 
seeded in each well of a 12-wells plate. The following day pro-
liferation medium was changed to differentiation medium and 
the cells were left to differentiate into myotubes for a week. 
The cells were then transduced with the AAV preparation at 
the chosen MOI in a total volume of 300 μl of medium with-
out serum. After 6 hours of incubation 1 ml of differentiation 
medium was added per well. Cells were incubated for 7 days 
in differentiation medium before harvesting for analysis.
Western blot. For dystrophin detection total protein was 
extracted  from  muscle  samples  with  Newcastle  buffer 
(3.8% SDS, 75 mmol/l Tris–HCl pH 6.7, 4 mol/l urea, 10% 
β-mercaptoethanol,  10%  glycerol,  0.001%  bromophenol 
blue)  and  quantified  using  the  bicinchoninic  acid  protein 
assay kit, according to the manufacturer’s instructions (Per-
bio Science, Brebieres, France). Samples were denatured at  
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95 °C for 5 minutes before 100 μg of protein was loaded in 
a 5% polyacrylamide gel with a 4% stacking gel. Gels were 
electrophoresed  for  4–5  hours  at  100 V  and  blotted  to  a 
PVDF membrane overnight at 50 V. Blots were blocked for 
1 hour with 10% nonfat milk in PBS–Tween (PBST) buffer. 
Dystrophin and α-actinin proteins were detected by prob-
ing the membrane with 1:100 dilution of NCL-DYS1 primary 
antibody  (monoclonal  antibody  to  dystrophin  R8  repeat; 
NovoCastra) and 1:200 dilution of α-actinin primary antibody 
(Santa Cruz Biotechnology), respectively. An incubation with 
a mouse horseradish peroxidase-conjugated secondary anti-
body (1:2,000) or goat horseradish peroxidase-conjugated 
secondary antibody (1:160,000) allowed visualization using 
ECL  Analysis  System  (GE  Healthcare).  Membranes  were 
converted to numerical pictures by scanning.
RNA  isolation  and  nested  RT-PCR  analysis.  RNA  were 
isolated from cells or muscle sections using TriZol Reagent 
according  to  the  manufacturer’s  instructions  (Invitrogen). 
RT-PCR was carried out on 300 ng of total RNA using the 
Access RT-PCR System (Promega). For human sequences 
analysis external primers Ex46Fo and Ex53Ro were used. 
The cDNA synthesis was carried out at 45 °C for 45 minutes, 
directly followed by the primary PCR of 30 cycles of 94 °C (30 
s), 55 °C (1 minute) and 72 °C (2 minutes). Two microlitres 
of the RT-PCR product was used for the nested PCR with 
the internal primers Ex47Fi and Ex52Ri for 22 cycles under 
identical cycling conditions. The same nested PCR condi-
tions were used for mouse sequences analysis, with external 
primers Ex20Fo and Ex26Ro, and internal primers Ex20Fi 
and Ex26Ri. Products were analyzed on 2% agarose gel.
Quantitative PCR. For each sample, 1 μg of total RNA was 
used for RT using the SuperScript II RT system (Invitrogen) 
and random hexamers as the priming nucleotides, according 
to the manufacturer’s instructions. For quantitative PCR anal-
ysis, 10 ng of the resulting cDNA was used per well. Com-
parative CT quantitative analysis of the exon 22-23 junction 
(Taqman Assay Mm01216934_m1; Applied Biosystems) and 
the exon 22-24 junction (Fw: CTGAATATGAAATAATGGAG-
GAGAGACTCG, Rev: CTTCAGCCATCCATTTCTGTAAGGT, 
probe:  FAM-ATGTGATTCTGTAATTTCC-NFQ)  was  per-
formed on each RNA sample. Reactions were performed in 
triplicate with the appropriate non-template controls using 
the cycle conditions: 95 °C for 10 minutes, and 40 cycles at 
95 °C for 15 seconds and 60 °C for 1 minute.
Data analysis. For each sample, the CTs for the 22–24 
assay (skipped dystrophin) are normalized to the CT for the 
22–23 assay (nonskipped dystrophin) to generate a delta-CT 
value. This involves the subtraction of the 22–23 CT from the 
22–24 Ct. The delta CT can be used to calculate the rela-
tive abundance in skipped dystrophin RNA species relative 
to full-length species.
An unpaired Student’s t-test was used to assess the statis-
tical significance of differences between the samples treated 
with  AAV-U7DTex23  and  the  samples  treated  with  AAV2-
MHCK-U7DTex23. A P value <0.05 was considered statisti-
cally significant. All results are expressed as mean values ± 
SEM.
Northern blot. Northern blots were realized on 7 μg of total 
RNA. Samples of total RNA were denaturated at 70 °C for 15 
minutes and loaded on a 15% Novex TBE-Urea precast gel 
(Invitrogen) along with 1 μl of γ-32P-labeled RNA Decade 
Markers (Ambion, Austin, TX). Gels were electrophoresed 
for 1 hour at 180 V in 2.5× TBE buffer, and transferred to a 
Hybond-N+ membrane (Amersham, UK) for 2 hours at 390 
mA in 2× TBE buffer. The membrane was UV-crosslinked 
with 100 mJ of energy and prehybridized in 10 ml of Rapid 
Hyb buffer (Amersham) containing salmon sperm DNA (50 
μg/ml)  at  42  °C.  For  radiolabeling  of  the  complementary 
DNA probe 50 pmol of oligonucleotide, U7DTex23 (5′-32P-
GTTAGTGTAAATGAACTTC-3′)  or  endogenous  U2snRNA 
(5′-32P-CTGATAAGAACAGATAC-3′), was end-labeled using 
γ-32P-ATP (Amersham, 6 000 Ci/mmol) and T4 PolyNucle-
otide Kinase (New England BioLabs, Ipswich, MA) for 1 hour 
at 37 °C. The probe was purified from unincorporated label 
using G-25 MicroSpin Columns (Amersham), and heated for 
1 minute at 95 °C before addition to the hybridization solu-
tion and incubation overnight at 42 °C. The following day 3 
successive washes of increasing stringency were realized 
for 15 minutes at 42 °C before placing the blots in a cas-
sette  with  an  autoradiogram. The  films  were  exposed  for   
72 hours.
MDX mice injection. Five-month-old mdx mice were anes-
thetized with isoflurane and injected in the tibialis anterior 
with 5 × 109, 2 × 1010, or 1011 viral genome copies of AAV2/8-
U7DTex23 or AAV2/8-MHCK-U7DTex23 (n = 3 for each con-
dition). For each mouse, contra-lateral muscle was injected 
with  PBS  as  a  negative  control.  Mice  were  sacrificed  4 
weeks after injection and tibialis anterior muscles were iso-
lated and snap frozen in liquid nitrogen-cooled isopentane. 
All animal experiments were carried out in Biomedical Sci-
ence Building, University of Oxford, Oxford, UK and per-
formed according to the guidelines and protocols approved 
by the Home Office.
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Figure S1. The MHCK enhancer increases GFP expression 
in myogenic cells.
Figure S2. Dose-dependent accumulation of read through 
U7 RNAs transcripts generated from AAV vector genome 
concatemers.
Figure  S3.  Northern  blot  analysis  of  (a)  U7DTex23  and 
(b) U7 transcripts expressed in 293T cells transfected with 
AAV  constructs  containing  either  the  SmOPT  sequence 
(AAUUUUGGAG, Figure 1a), or the native U7 Sm sequence 
(AAUUUGUCUAG). 
Figure S4. The MHCK enhancer loses its tissue specificity 
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